(PFS) after initial surgery, and PFS after the date of the final chemotherapy were analyzed by Kaplan-Meier estimate. RESULTS: A total of 52 patients met the ...
Neuro-Oncology 17:v18 – v40, 2015. doi:10.1093/neuonc/nov204.38
NEURO-ONCOLOGY
Abstracts
ATPS-38. ASSESSMENT OF OPTIMIZED THERAPEUTIC TERM WITH TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA Soko Ikuta, Takashi Maruyama, Katsuya Maebayashi, Masayuki Nitta, Taiichi Saito, Manabu Tamura, Atsushi Fukui, Saori Okamoto, Hiroshi Iseki, Takakazu Kawamata, and Yoshihiro Muragaki; Tokyo Women’s Medical University, Tokyo, Japan BACKGROUND: Standard therapeutics for glioblastoma is tumor removal followed by radiotherapy and chemotherapy with temozolomide (TMZ). Additional six cycles of TMZ is usually given, but it is unclear whether six cycles is sufficient to reduce recurrence. In our series, 25% of patients with GBM treated with TMZ lived more than one year without recurrence, and most of them received 12 cycles or more of TMZ chemotherapy. We retrospectively assessed the efficacy of long term TMZ in these case series. METHODS: Patients with newly diagnosed GBM, treated with 12 cycles or more TMZ after concomitant radiotherapy without relapse, were consecutively sampled at our institution from 2006 to 2014. The patents were categorized into 4 groups according to number of TMZ chemotherapy A) 12 cycles, B) 24 cycles, C) more than 24 cycles until relapse, D) beyond 12 cycles (included B, C). Progression free survival (PFS) after initial surgery, and PFS after the date of the final chemotherapy were analyzed by Kaplan-Meier estimate. RESULTS: A total of 52 patients met the criteria. Groups A, B, C and D included 12, 14, 12 and 40 patients, respectively. Each group had similar backgrounds. Median survival time (MST) and PFS of all patients was 6.8 and 4.3 years, respectively. There were no significant differences in PFS after the initial surgery between group A and B (p ¼ 0.5889) and between C and D (p ¼ 0.9243). Also, PFS after the final date of chemotherapy between group A and D (p ¼ 0.5778), C and D (p ¼ 0.8498) showed no difference, suggesting no benefit of more than 12 cycles of chemotherapy. CONCLUSION: This study suggested that patients with newly diagnosed GBM who are able to continue 12 cycles of TMZ chemotherapy can expect 6.3 years of OS and 4.3 years of PFS. More than 12 cycles of chemotherapy showed no additional survival benefit.
Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2015.
